1832 Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-58,086
| Closed | -$3.45M | – | 661 |
|
|
2025
Q4 | $3.45M | Buy |
58,086
+35,547
| +158% | +$1.94M | ﹤0.01% | 470 |
|
|
2025
Q3 | $1.22M | Sell |
22,539
-3,495
| -13% | -$200K | ﹤0.01% | 560 |
|
|
2025
Q2 | $1.43M | Buy |
+26,034
| New | +$1.53M | ﹤0.01% | 538 |
|
|
2024
Q4 | – | Sell |
-1,164,391
| Closed | -$81.8M | – | 667 |
|
|
2024
Q3 | $81.8M | Buy |
1,164,391
+1,141,200
| +4,921% | +$95.4M | 0.06% | 156 |
|
|
2024
Q2 | $1.91M | Buy |
23,191
+3,470
| +18% | +$289K | ﹤0.01% | 502 |
|
|
2024
Q1 | $1.72M | Sell |
19,721
-717,500
| -97% | -$64.2M | ﹤0.01% | 530 |
|
|
2023
Q4 | $71.1M | Buy |
737,221
+263,781
| +56% | +$23.3M | 0.1% | 150 |
|
|
2023
Q3 | $41.9M | Buy |
473,440
+92,719
| +24% | +$8.25M | 0.06% | 186 |
|
|
2023
Q2 | $33M | Buy |
380,721
+229,415
| +152% | +$21.6M | 0.04% | 216 |
|
|
2023
Q1 | $14.7M | Sell |
151,306
-974,500
| -87% | -$101M | 0.02% | 297 |
|
|
2022
Q4 | $117M | Sell |
1,125,806
-276,246
| -20% | -$25.9M | 0.19% | 97 |
|
|
2022
Q3 | $119M | Buy |
1,402,052
+200,170
| +17% | +$17.8M | 0.22% | 93 |
|
|
2022
Q2 | $99.6M | Buy |
1,201,882
+701,500
| +140% | +$55.9M | 0.17% | 113 |
|
|
2022
Q1 | $38.1M | Buy |
500,382
+110,490
| +28% | +$9.24M | 0.05% | 240 |
|
|
2021
Q4 | $34.7M | Buy |
389,892
+60,842
| +18% | +$5.02M | 0.06% | 202 |
|
|
2021
Q3 | $25.4M | Buy |
329,050
+217,413
| +195% | +$17.2M | 0.05% | 239 |
|
|
2021
Q2 | $9.17M | Hold |
111,637
| – | – | 0.02% | 319 |
|
|
2021
Q1 | $8.28M | Buy |
+111,637
| New | +$9.12M | 0.02% | 309 |
|
|
2020
Q3 | – | Sell |
-979,300
| Closed | -$119M | – | 685 |
|
|
2020
Q2 | $119M | Buy |
979,300
+940,078
| +2,397% | +$93.4M | 0.36% | 79 |
|
|
2020
Q1 | $3.22M | Buy |
+39,222
| New | +$3.38M | 0.01% | 341 |
|
|
2015
Q4 | – | Sell |
-9,900
| Closed | -$1.05M | – | 660 |
|
|
2015
Q3 | $1.05M | Sell |
9,900
-1,600
| -14% | -$214K | ﹤0.01% | 390 |
|
|
2015
Q2 | $1.57M | Sell |
11,500
-2,000
| -15% | -$248K | 0.01% | 426 |
|
|
2015
Q1 | $1.69M | Buy |
13,500
+1,100
| +9% | +$117K | 0.01% | 384 |
|
|
2014
Q4 | $1.12M | Sell |
12,400
-7,100
| -36% | -$590K | ﹤0.01% | 433 |
|
|
2014
Q3 | $1.41M | Buy |
19,500
+100
| +0.5% | +$6.57K | ﹤0.01% | 426 |
|
|
2014
Q2 | $1.21M | Hold |
19,400
| – | – | ﹤0.01% | 445 |
|
|
2014
Q1 | $1.29M | Sell |
19,400
-2,100
| -10% | -$155K | ﹤0.01% | 442 |
|
|
2013
Q4 | $1.51M | Buy |
21,500
+6,300
| +41% | +$428K | 0.01% | 385 |
|
|
2013
Q3 | $1.1M | Buy |
+15,200
| New | +$1.01M | ﹤0.01% | 336 |
|
Other funds holding BMRN
VCM
VPM
1832 Asset Management's BMRN Position: Q1 2026 in Review
1832 Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2026, closing a stake of 58,086 shares — an estimated $3.45M sold.
1832 Asset Management first reported a position in BMRN in Q3 2013 and held it in 29 quarters. The position peaked at $119M in Q3 2022. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.
- 1832 Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- 1832 Asset Management sold 58,086 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $3.45M.
- 1832 Asset Management first reported a position in BioMarin Pharmaceuticals in Q3 2013 and held it in 29 quarters.
- 1832 Asset Management's BioMarin Pharmaceuticals position peaked at $119M in Q3 2022.
- 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.
Based on 1832 Asset Management's 13F filing for Q1 2026, filed 14 May 2026.